Format

Send to

Choose Destination

Use of intravenous immunoglobulin G (IVIG).

Author information

1
Department of Medicine, Allergy, Immunology, Rheumatology Unit, School of Medicine and Dentistry, University of Rochester, 595 Elmwood Ave, Room G-6454, Rochester, NY 14642, USA. john_looney@urmc.rochester.edu

Abstract

Intravenous immunoglobulin G (IVIG) has become increasingly important both as replacement therapy in primary and acquired humoral immunodeficiency and as an immunomodulatory therapy in autoimmune disease and transplantation. Multiple potential mechanisms for the effects of IVIG have now been recognized but the contribution of each mechanism in different diseases is uncertain. IVIG is generally well tolerated but serious side effects can occur and need to be addressed. IVIG has Food and Drug Administration (FDA) approval for a half dozen indications but these account for only about half the use of IVIG. This chapter reviews the development of IVIG for primary immunodeficiency, the evidence for efficacy of IVIG in autoimmune and inflammatory conditions, the risks associated with administration of IVIG, and steps that can be taken to minimize adverse events.

PMID:
16377538
DOI:
10.1016/j.beha.2005.01.032
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center